Related references
Note: Only part of the references are listed.Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) plus Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
Alice L. Yu et al.
CLINICAL CANCER RESEARCH (2021)
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Ruth Ladenstein et al.
CANCERS (2020)
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma
Sascha Marx et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy
Solin Ali et al.
FRONTIERS IN IMMUNOLOGY (2020)
Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells
Karin Toews et al.
MOLECULAR CARCINOGENESIS (2020)
Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition
Julie Voeller et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
David T. W. Jones et al.
NATURE REVIEWS CANCER (2019)
The landscape of genomic alterations across childhood cancers
Susanne N. Groebner et al.
NATURE (2018)
Phase II trial of irinotecan/temozolomide/dinutuximab/gr anulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A report from the Children's Oncology Group (COG).
Rajen Mody et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Ruth Ladenstein et al.
LANCET ONCOLOGY (2018)
High-Risk Neuroblastoma Treatment Review
Valeria Smith et al.
CHILDREN-BASEL (2018)
2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors
Thorsten Simon et al.
KLINISCHE PADIATRIE (2017)
Immunotherapy with the trifunctional anti-CD20xanti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease
Anna Kieslich et al.
LEUKEMIA & LYMPHOMA (2017)
Affinity of human IgG subclasses to mouse Fc gamma receptors
Gillian Dekkers et al.
MABS (2017)
MYCN amplification is associated with repressed cellular immunity in neuroblastoma: an In Silico immunological analysis of TARGET Database
Peng Zhang et al.
FRONTIERS IN IMMUNOLOGY (2017)
MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma
Elisa Brandetti et al.
ONCOIMMUNOLOGY (2017)
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
Eugene A. Zhukovsky et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors
Ming Cheng et al.
ONCOIMMUNOLOGY (2016)
Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies
Friedhelm R. Schuster et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy
Ming Cheng et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
Hong Xu et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Trifunctional Bispecific Antibodies Induce Tumor-Specific T Cells and Elicit a Vaccination Effect
Nina Eissler et al.
CANCER RESEARCH (2012)
Treatment and Outcomes of Patients With Relapsed, High-Risk Neuroblastoma: Results of German Trials
Thorsten Simon et al.
PEDIATRIC BLOOD & CANCER (2011)
Activation of human complement by mouse and mouse/human chimeric monoclonal antibodies
J. SEINO et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Neuroblastoma: Biology, Prognosis, and Treatment
Julie R. Park et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia
Linda S. Sorkin et al.
PAIN (2010)
The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
Michael Jaeger et al.
CANCER RESEARCH (2009)
Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels
Michael Stanglmaier et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma
Brian H. Kushner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice
Y Zeng et al.
MOLECULAR IMMUNOLOGY (2005)
Two new trifunctional antibodies for the therapy of human malignant melanoma
P Ruf et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
P Ruf et al.
BLOOD (2001)
Share Paper
